Clinical Trial Update: Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib [Phase 4]

View source ↗

Summary

A Phase 4 study assessing discontinuation and re-treatment in Tenosynovial Giant Cell Tumor patients previously treated with pexidartinib; the trial is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tenosynovial Giant Cell Tumor

Drugs mentioned

• Pexidartinib (pexidartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Tenosynovial Giant Cell Tumor | Phase 4 | Status: COMPLETED | Results posted: 2024-12-30